Entrada Therapeutics Q1 net loss beats analyst estimates
Entrada Therapeutics Inc TRDA | 0.00 |
Overview
U.S. biopharma firm's Q1 net loss narrowed versus analyst expectations
Q1 collaboration revenue fell sharply due to winding down of Vertex partnership
Company reported positive topline results from Duchenne muscular dystrophy trial
Outlook
Entrada expects to report ELEVATE-45-201 Cohort 1 data in mid-2026
Company expects to report ELEVATE-44-201 open-label and Cohort 2 data by year-end 2026
Entrada expects cash runway into Q3 2027
Result Drivers
COLLABORATION REVENUE DROP - Revenue fell due to substantial completion of Vertex partnership research activities
HIGHER R&D SPEND - Increased R&D expenses driven by additional costs for DMD programs
POSITIVE CLINICAL DATA - Announced favorable safety, tolerability and early functional benefit from ELEVATE-44-201 Cohort 1 in DMD
Company press release: ID:nGNXD5N1w
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q1 Collaboration Revenue |
|
$875,000 |
|
Q1 Net Income |
Beat |
-$39.72 mln |
-$45.10 mln (7 Analysts) |
Q1 Income From Operations |
|
-$42.30 mln |
|
Q1 Operating Expenses |
|
$43.18 mln |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.